GxP documentation is one of the foundations of quality, regulatory compliance, and patient safety in pharmaceutical organizations. The principle behind its management is well known: “If it isn’t documented, it didn’t happen.” Therefore, keeping procedures and work instructions up to date is essential for successfully navigating audits, regulatory inspections, and internal reviews, while also ensuring the effectiveness of the Quality Management System.
What is GxP documentation?
GxP documentation includes the controlled set of documents and records that demonstrate how regulated activities are planned, performed, reviewed, and maintained in compliance with applicable Good Practices, including Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Pharmacovigilance Practice (GVP).
Effective GxP documentation must be accurate, complete, legible, timely, easily retrievable, and protected from unauthorized changes. In addition, it must ensure full traceability of activities, allowing organizations to identify who performed an operation, when it was carried out, which materials, equipment, or systems were used, which procedure was followed, and what outcome was achieved.
In this context, Data Integrity and ALCOA+ principles are fundamental. These principles require data to be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available throughout the required record lifecycle.
From a regulatory perspective, documentation provides objective evidence that a process is under control and that critical activities have been performed in accordance with approved requirements and applicable regulations. Operationally, it standardizes processes, facilitates knowledge transfer, and supports business continuity. Documentation also plays a key role in training, deviation investigations, and the reconstruction of the history of a batch, clinical study, distribution activity, or quality-related decision.
For these reasons, every GxP document must be managed throughout its entire lifecycle—from drafting and approval to use, periodic review, archiving, and retention according to company procedures and regulatory requirements.
SOPs that require continuous review
Standard Operating Procedures (SOPs) should undergo periodic review to ensure they accurately reflect current activities, applicable requirements, and evolving business processes. However, some procedures require particularly rigorous oversight due to their impact on the Quality Management System.
These include SOPs governing document management, Change Control, deviation management, and CAPA (Corrective and Preventive Actions). Such procedures directly affect an organization’s ability to control changes, manage non-conformities, implement effective corrective actions, and demonstrate traceability of quality-related decisions.
When should a procedure be updated?
Documentation updates should be initiated whenever organizational changes, new technologies, or modifications affecting manufacturing processes, facilities, equipment, computerized systems, or operating methods are introduced.
A procedure may also require revision following the introduction of new products, materials, suppliers, or contract service providers. Likewise, an approved Change Control may trigger the need to align related documentation.
For example, software validation, the replacement of a critical supplier, or the implementation of new operating practices may require coordinated updates to SOPs, work instructions, forms, and associated records. This approach helps avoid inconsistencies and ensures that documentation remains aligned with actual processes.
Internal audits, regulatory inspections, product complaints, recurring deviations, ineffective CAPAs, or unfavorable quality trends may also highlight the need to revise procedures and work instructions. In these situations, documentation review is not simply an administrative task. Instead, it becomes a valuable tool for correcting misalignments, preventing recurring issues, and strengthening process control.
The importance of periodic SOP reviews
Beyond updates driven by specific changes, SOPs should be reviewed periodically according to timelines defined by the company’s Quality Management System.
A periodic review helps determine whether document content remains appropriate, effective, and aligned with current operations. At the same time, it provides an opportunity to identify redundant procedures, remove obsolete references, harmonize related documents, and improve the clarity of operational instructions.
As a result, a well-structured review process helps maintain an efficient, up-to-date, and compliant documentation system that supports organizational quality objectives.
Common mistakes to avoid
Several recurring issues are frequently identified during audits and inspections. These include procedures that do not reflect actual practices, overdue document reviews, unclear responsibilities, the use of obsolete versions, insufficiently documented training, and the lack of effectiveness checks following SOP implementation.
A particularly common mistake is treating document review as an isolated activity disconnected from Change Control, deviation management, CAPA processes, personnel training, and impact assessments.
Such weaknesses can lead to operational ambiguity, execution errors, reduced traceability, and difficulties in demonstrating compliance during audits and inspections. In more serious situations, ineffective document management may result in inspection observations, additional CAPAs, delays in batch release, and reduced confidence in the Pharmaceutical Quality System.
Conclusions
Keeping GxP documentation up to date is not merely a regulatory requirement, it is a strategic factor for ensuring the quality of pharmaceutical processes and products. Investing in the continuous review of procedures helps reduce compliance risks, strengthen quality systems, improve operational efficiency, and support continuous improvement initiatives.
In addition, maintaining current documentation promotes a culture of inspection readiness, meaning the ability to demonstrate at any time that processes, activities, and decisions are managed in a controlled and compliant manner.
Ultimately, a robust, consistent, and operationally aligned documentation system is essential for successfully managing audits and inspections while reinforcing the confidence of customers, regulatory authorities, and stakeholders in the organization’s quality standards.
References
- European Commission. EudraLex Volume 4 — EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use.
- European Medicines Agency (EMA). Guidance on Good Manufacturing Practice and Good Distribution Practice: Questions and Answers.
- Pharmaceutical Inspection Co-operation Scheme (PIC/S). PIC/S Guide to Good Manufacturing Practice for Medicinal Products.
- S. Food and Drug Administration (FDA). 21 CFR Part 11 — Electronic Records; Electronic Signatures.
- S. Food and Drug Administration (FDA). Data Integrity and Compliance With Drug CGMP: Guidance for Industry.
- International Council for Harmonisation (ICH). ICH Q9(R1): Quality Risk Management.
- International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System.
- European Commission. Guidelines on Good Distribution Practice of Medicinal Products for Human Use.
- European Medicines Agency (EMA). Guideline on Good Pharmacovigilance Practices (GVP).